Published in Thromb Res on January 01, 1979
Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest (1982) 1.45
Inactivation of kallikrein in human plasma. J Clin Invest (1983) 1.27
Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest (1993) 0.93
Kinin-forming and destroying activities of cell homogenates. J Physiol (1965) 1.69
Studies on plasma antiplasmin activity using a new plasmin specific chromogenic tripeptide substrate. Thromb Res (1979) 1.38
Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost (1992) 1.37
Some aspects of fibrin clot lysis and its inhibition by human serum. Thromb Diath Haemorrh (1967) 1.15
Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med Biol (1979) 1.15
The influence of various plasma components on the lysis of dilute human blood clots. Thromb Diath Haemorrh (1969) 1.05
Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol (2000) 0.92
Effect of diluents on blood clot lysis. J Clin Pathol (1967) 0.92
Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock (1982) 0.91
Falls in plasma levels of prekallikrein, high molecular weight kininogen, and kallikrein inhibitors during lethal endotoxin shock in dogs. Thromb Res (1978) 0.89
Modulation of morphological differentiation of human neuroepithelial cells by serine proteases: independence from blood coagulation. EMBO J (1989) 0.89
Plasma kallikrein-kinin system in septicemia. Arch Surg (1983) 0.88
Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int (1986) 0.87
Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol (2001) 0.87
Experimental acute pancreatitis in dogs. I. Hypotensive effect induced by pancreatic exudate. Scand J Gastroenterol (1968) 0.87
Experimental acute pancreatitis in dogs. IV. The relationship between phospholipase A and the histamine-releasing and hypotensive effects of pancreatic exudate. Scand J Gastroenterol (1969) 0.87
Serum inhibitors in fibrinolysis. Br J Haematol (1975) 0.85
Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma. Thromb Res (1982) 0.85
Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost (1999) 0.85
Plasma kallikrein activity and prekallikrein levels during endotoxin shock in dogs. Eur Surg Res (1978) 0.84
Phospholipase activity in pancreatic exudate in experimental acute pancreatitis. Scand J Gastroenterol (1967) 0.84
Experimental acute pancreatitis in dogs. II. Histamine release induced by pancreatic exudate. Scand J Gastroenterol (1969) 0.84
FXII. Blut (1990) 0.83
The measurement of fibrinolysis in the rat. Thromb Diath Haemorrh (1971) 0.83
The origin of fibrin breakdown products and the interpretation of their appearance in the circulation. J Clin Pathol (1972) 0.82
The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb Res (1978) 0.81
Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock. Adv Shock Res (1980) 0.81
Experimental acute pancreatitis in dogs. 3. The nature of the phospholipase activity of pancreatic exudate. Scand J Gastroenterol (1969) 0.81
Myocardial blood flow and metabolism in the diving seal. Am J Physiol (1982) 0.80
Uncontrolled plasma proteolysis: a major threat to the septicemic patient. Resuscitation (1986) 0.80
Determination of plasma aprotinin levels by functional and immunologic assays. Blood Coagul Fibrinolysis (2001) 0.79
FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery. Immunopharmacology (1999) 0.79
Activation of human plasma prekallikrein: influence of activators, activation time and temperature and inhibitors. Thromb Res (1978) 0.78
Changes in plasminogen levels, plasmin activity and activity of antiplasmins during endotoxin shock in dogs. Eur Surg Res (1978) 0.78
Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model. Immunopharmacology (1996) 0.78
Inhibition of the amidolytic activity of urokinase by human plasma. Thromb Res (1980) 0.78
Recurrent abortion-antibodies to factor XII or a decrease in factor XII levels? Fertil Steril (2001) 0.78
Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock. Thromb Res (1980) 0.77
Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss. Blood Coagul Fibrinolysis (1992) 0.77
Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma. Adv Exp Med Biol (1986) 0.77
Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. Thromb Haemost (2002) 0.77
More on: Discovery of alpha2-plasmin inhibitor and its congenital deficiency. J Thromb Haemost (2006) 0.76
Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. Adv Exp Med Biol (1986) 0.76
The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome. J Thromb Haemost (2005) 0.76
Studies on pathological plasma proteolysis in patients with septicemia. Scand J Clin Lab Invest Suppl (1985) 0.76
Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model. Perfusion (2001) 0.76
Factor XII determinations and lupus anticoagulants. Blood Coagul Fibrinolysis (1997) 0.75
Antiplasmin concentrations after surgery. Br Med J (1979) 0.75
Influence of some pathogenic bacteria on kinin formation and destruction. Br J Pharmacol Chemother (1965) 0.75
Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost (1993) 0.75
More on: Pathogenic antibodies to coagulation factors. Part II: Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, protein C and von Willebrand factor. J Thromb Haemost (2006) 0.75
Studies on components of the plasma kallikrein system as a risk factor in diabetics undergoing cardiopulmonary bypass. Agents Actions Suppl (1992) 0.75
Changes in the kallikrein-kinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol (1989) 0.75
Aprotinin in therapeutic doses inhibits chromogenic peptide substrate assays for protein C. Thromb Res (1994) 0.75
Chromogenic substrate assays for studying components of the plasma kallikrein system in health and disease. Adv Exp Med Biol (1983) 0.75
Blood cells and coagulation during experimental lung insufficiency in dogs. Acta Chir Scand Suppl (1980) 0.75
Inhibition of beta-FXIIa in plasma of volunteers and polytraumatized patients. Prog Clin Biol Res (1987) 0.75
The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis (1993) 0.75
Changes in components of the KK-system after recirculation and the addition of plasma kallikrein. Adv Exp Med Biol (1989) 0.75
Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model. Blood Coagul Fibrinolysis (1994) 0.75
[The cell membrane and intensive medicine]. Tidsskr Nor Laegeforen (1977) 0.75
Changes in plasma levels of prekallikrein, kallikrein, high molecular weight kininogen and kallikrein inhibitors during lethal endotoxin shock in dogs. Haemostasis (1978) 0.75
Alterations of plasmin activity, plasminogen levels and activity of antiplasmins during endotoxin shock in dogs. Haemostasis (1978) 0.75
Factor XII levels in patients after abdominal surgery. Adv Exp Med Biol (1989) 0.75
Studies on Hageman factor, plasma prekallikrein, kallikrein "like" activity and kallikrein inhibition in plasma samples from normal subjects and clinical material. Adv Exp Med Biol (1983) 0.75
Plasma antiplasmin activities in experimental lung insufficiency. Acta Chir Scand Suppl (1980) 0.75
[Institute for Surgical Research at the Rikshospitalet]. Tidsskr Nor Laegeforen (1974) 0.75
Studies on shock during extracorporeal circulation during aorto-coronary bypass operations. Prog Clin Biol Res (1987) 0.75
[Acute pancreatitis. Aspects of the pathophysiology (author's transl)]. Leber Magen Darm (1976) 0.75
Prekallikrein activator. Thromb Haemost (1984) 0.75
Studies on the inhibition of plasma kallikrein, C1-esterase and beta-FXIIa in the presence and the absence of heparins. Adv Exp Med Biol (1989) 0.75
Levels of IgA, IgM, IgG and complement components during extracorporal circulation. Adv Exp Med Biol (1986) 0.75
Changes in antiplasmin and plasmin activities during extreme hemodilution and open heart surgery in dogs. Eur Surg Res (1979) 0.75
Effect of high and low molecular weight heparin preparations on chromogenic substrate assays for components of the kallikrein-kinin system. Adv Exp Med Biol (1986) 0.75
Chromogenic peptide substrate assays for determining components of the plasma kallikrein system. Scand J Clin Lab Invest Suppl (1985) 0.75
Inter-alpha-antiplasmin: its distinction from antiactivator. Thromb Res (1978) 0.75
Studies on components of the plasma kallikrein and complement systems in plasma and serum samples from normal individuals and patients with hereditary angioedema. Adv Exp Med Biol (1983) 0.75
Studies on synthetic peptide substrates for F XII enzymes. Adv Exp Med Biol (1986) 0.75
Activation of the kallikrein-kinin system during experimental lung insufficiency in dogs. Acta Chir Scand Suppl (1980) 0.75
Parameters of the kallikrein-kinin, coagulation and fibrinolytic systems as early indicators of kidney transplant rejection. Nephron (1988) 0.75